We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cypralis, J&J Collaborate
News

Cypralis, J&J Collaborate

Cypralis, J&J Collaborate
News

Cypralis, J&J Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cypralis, J&J Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cyclophilin inhibitors on the market or in development are non-selective between the four commonly screened cyclophilin isoforms A, B, C and D. Cypralis and Janssen are undertaking a joint research program to generate a new class of CNS penetrant, selective inhibitors of cyclophilin D applicable to targeting degenerative diseases including CNS degeneration. The medicinal chemistry and PPIase screening will be sub-contracted to Selcia Limited.

Simon Kerr, CEO of Cypralis commented: ‘We are delighted to be collaborating with Janssen in order to develop a novel class of cyclophilin D inhibitors. We are hopeful that this effort will pave the way towards a new approach to the treatment of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.’

Advertisement